Tumor-Derived PGE2 Gives NK Cells a Headache

Nelson H Knudsen; Robert T Manguso

doi:10.1016/j.immuni.2020.11.018

Tumor-Derived PGE2 Gives NK Cells a Headache

Immunity. 2020 Dec 15;53(6):1131-1132. doi: 10.1016/j.immuni.2020.11.018.

Authors

Nelson H Knudsen¹, Robert T Manguso²

Affiliations

¹ Center for Cancer Research, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA; Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA, USA.
² Center for Cancer Research, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA; Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA, USA. Electronic address: [email protected].

PMID: 33326763
DOI: 10.1016/j.immuni.2020.11.018

Abstract

Tumors use active immunosuppressive mechanisms to evade immune recognition and shape the local inflammatory environment. In this issue of Immunity, Bonavita et al. report that tumor-derived PGE2 blocks early activation of natural killer cells and interferes with subsequent adaptive immune cell recruitment to the tumor.

Publication types

Comment

MeSH terms

Dinoprostone*
Headache
Humans
Immune Checkpoint Inhibitors
Killer Cells, Natural
Neoplasms*
Phenotype

Substances

Immune Checkpoint Inhibitors
Dinoprostone